Global Urinary Tract Infection (UTI) Market to be Worth 9.89 Billion USD by 2023

Global Urinary tract infection (UTI) treatment drugs market is valued at USD 8 billion in 2016, which is expected to reach to USD 9.89 billion in 2023 at a CAGR of 3.6 %. Urinary tract infection (UTI treatment) is the infection of the lower or upper urinary tract caused by bacterial agents such as Escherichia coli, Staphylococcus saprophyticus, and others. The symptoms associated with UTI are pain during urination, frequent urination and a feeling of urination despite having an empty bladder.

Get Exclusive Sample of Report @ https://www.marketresearchfuture.com/sample_request/6138

Some of the primary causes of UTI include unsafe intercourse, diabetes, and obesity, lack of hygiene. Due to the inherent complicated female anatomy, UTI infection affects females more than males. The World Health Organization (WHO) estimates that almost 50 % of the women suffer from UTI treatment at some point in time in their lives resulting in more than 1 million hospitalizations per year. Almost 1 % of boys and 3 to 8 % of girls are diagnosed with UTI treatment. The annual cost of UTI treatment infections treatment is higher than $1 billion in the U.S. alone. The incidence rate of UTIs is 0.91 % of total population, and 2.05 % for a female population with E.coli being the most common pathogen accounting for 80 % to 90 % of all the cases.

Rise in hospital-borne infections, the emergence of drug-resistant bacteria, growing the geriatric population, childbirth, and increasing health awareness especially about women health. Growing used of catheters is the fastest driver of catheter-associated UTI. According to Centres for Disease Control and Prevention among hospitals acquired infections, approximately 75 % are associated with a urinary catheter.

Global Urinary tract infection (UTI) Market Players:

Some of the dominant vendors operating in the report are Bayer AG, GlaxoSmithKline Novartis AG, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Johnson & Johnson, and others..

Urinary tract infection (UTI) Market Segmentation:

The Global UTI treatment Market is segmented based on drug class, clinical indications, end users, and regions. Based on drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles, and others. Based on clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis and others. Based on end users the market is segmented into hospitals, self-administered and others. Based on the regions, the market has been segmented as North America, Europe, Asia Pacific Middle East and Africa and rest of the world.

Urinary tract infection (UTI) Market Regional Analysis:

North America led by the U.S. accounts for the maximum market share of the global UTI treatment market followed by Europe. The recent regulatory shift in the U.S. such as the implementation of Affordable Care Act and Hospital Readmissions Reduction Program coupled with Medicare initiative to penalize unnecessary patient readmissions is expected to charge the U.S UTI treatment market. Europe has a higher hospitalization rate than the U.S. despite the U.S. having substantial spending on healthcare.

However, these markets are stagnant, and there is a definite shift towards the Asia Pacific regions led by India and China. The Asia Pacific will be the fastest growing market, and the growth will be driven by China, and India as these nations have colossal population and the low cost of UTI treatment drugs.

Browse Complete Report @ https://www.marketresearchfuture.com/upcoming-reports/urinary-tract-infection-market-6138

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.